Targeting GPD1 (such as small molecule inhibitors) may provide a new strategy for the comorbidity of NAFLD and CAD by reshaping macrophage function and improving metabolic abnormalities and inflammation. The gene discussed is GPD1; the disease is coronary artery disorder.